| Year |
Citation |
Score |
| 2020 |
Davies K, Barth M, Armenian S, Audino AN, Barnette P, Cuglievan B, Ding H, Ford JB, Galardy PJ, Gardner R, Hanna R, Hayashi R, Kovach AE, Machnitz AJ, Maloney KW, et al. Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network : Jnccn. 18: 1105-1123. PMID 32755986 DOI: 10.6004/Jnccn.2020.0036 |
0.377 |
|
| 2019 |
Verma A, Chen K, Bender C, Gorney N, Leonard W, Barnette P. PEGylated asparaginase desensitization: an effective and feasible option for pediatric patients with acute lymphoblastic leukemia who have developed hypersensitivity to pegaspargase in the absence of asparaginase availability. Pediatric Hematology and Oncology. 1-10. PMID 31296092 DOI: 10.1080/08880018.2019.1634778 |
0.391 |
|
| 2018 |
Verma A, Chen K, Johnsen J, Barnette P. Pegylated E. coli Asparaginase Desensitization: An Effective and Feasible Option for Pediatric Patients with Acute Lymphoblastic Leukemia Who Have Developed Hypersensitivity to Pegaspargase in the Absence of Asparaginase Erwinia Chrysanthemi availability Blood. 132: 5205-5205. DOI: 10.1182/Blood-2018-99-119866 |
0.372 |
|
| 2017 |
Topp MS, Stelljes M, Zugmaier G, Barnette P, Heffner LT, Trippett T, Duell J, Bargou RC, Holland C, Benjamin JE, Klinger M, Litzow MR. Blinatumomab retreatment after relapse in patients with relapsed/refractory B-precursor acute lymphoblastic leukemia. Leukemia. PMID 28990581 DOI: 10.1038/Leu.2017.306 |
0.391 |
|
| 2017 |
Hunger SP, Saha V, Devidas M, Valsecchi MG, Foster JG, Cazzaniga G, Reshmi SC, Borowitz M, Moorman A, Heerema NA, Carroll AJ, Barnette P, Gramatges MMM, Maloney K, Sun W, et al. CA180-372: An International Collaborative Phase 2 Trial of Dasatinib and Chemotherapy in Pediatric Patients with Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Blood. 130: 98-98. DOI: 10.1182/Blood.V130.Suppl_1.98.98 |
0.389 |
|
| 2016 |
von Stackelberg A, Locatelli F, Zugmaier G, Handgretinger R, Trippett TM, Rizzari C, Bader P, O'Brien MM, Brethon B, Bhojwani D, Schlegel PG, Borkhardt A, Rheingold SR, Cooper TM, Zwaan CM, ... Barnette P, et al. Phase I/Phase II Study of Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 4381-4389. PMID 27998223 DOI: 10.1200/Jco.2016.67.3301 |
0.408 |
|
| 2016 |
Meyer JA, Zhou D, Mason CC, Downie JM, Rodic V, Abromowitch M, Wistinghausen B, Termuhlen AM, Angiolillo AL, Perkins SL, Barnette P, Schiffman JD, Miles RR. Genomic characterization of pediatric B-lymphoblastic lymphoma and B-lymphoblastic leukemia using formalin-fixed tissues. Pediatric Blood & Cancer. PMID 27957801 DOI: 10.1002/Pbc.26363 |
0.323 |
|
| 2016 |
Vo KT, Edwards JV, Epling CL, Sinclair E, Hawkins DS, Grier HE, Janeway KA, Barnette P, McIlvaine E, Krailo M, Barkauskas DA, Matthay KK, Womer RB, Gorlick R, Lessnick SL, et al. Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26861456 DOI: 10.1158/1078-0432.Ccr-15-2516 |
0.367 |
|
| 2015 |
Topp MS, Stelljes M, Zugmaier G, Barnette P, Heffner LT, Trippett TM, Bargou RC, Holland C, Benjamin J, Litzow MR. Re-exposure to blinatumomab after CD19-positive relapse: Experience from three trials in patients (pts) with relapsed/refractory B-precursor acute lymphoblastic leukemia (R/R ALL). Journal of Clinical Oncology. 33: 7051-7051. DOI: 10.1200/Jco.2015.33.15_Suppl.7051 |
0.353 |
|
| 2015 |
Handgretinger R, Gore L, Zugmaier G, Locatelli F, Zwaan CM, Bhojwani D, Bader P, O'Brien MM, Trippett TM, Brethon B, Rizzari C, Schlegel PG, Michel G, Barnette P, Messina C, et al. Allogeneic Hematopoietic Stem Cell Transplantation (alloHSCT) Following Blinatumomab-Induced Remission in Pediatric Patients with Relapsed/Refractory (r/r) B-Precursor Acute Lymphoblastic Leukemia (ALL): Preliminary Results from a Phase I/II Stud Biology of Blood and Marrow Transplantation. 21. DOI: 10.1016/J.Bbmt.2014.11.284 |
0.346 |
|
| 2014 |
Gore L, Locatelli F, Zugmaier G, Zwaan CM, Bhojwani D, Handgretinger R, Bader P, O'Brien MM, Trippett TM, Brethon B, Rizzari C, DuBois SG, Schlegel PG, Barnette P, Messina C, et al. Initial Results from a Phase 2 Study of Blinatumomab in Pediatric Patients with Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia Blood. 124: 3703-3703. DOI: 10.1182/Blood.V124.21.3703.3703 |
0.447 |
|
| 2012 |
Tap WD, Demetri G, Barnette P, Desai J, Kavan P, Tozer R, Benedetto PW, Friberg G, Deng H, McCaffery I, Leitch I, Badola S, Chang S, Zhu M, Tolcher A. Phase II study of ganitumab, a fully human anti-type-1 insulin-like growth factor receptor antibody, in patients with metastatic Ewing family tumors or desmoplastic small round cell tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 1849-56. PMID 22508822 DOI: 10.1200/Jco.2011.37.2359 |
0.349 |
|
| 2012 |
Rabin KR, Mason CC, Gurusiddappa S, Leung HE, Morrison DJ, Bhojwani D, Barnette P, South ST, Miles RR, Devidas M, Pession A, Basso G, Potter NE, Kearney L, Moorman AV, et al. IKZF1 and 22q11.22 Deletions and PDGFRA Gains Are Associated with Poor Outcome in Down Syndrome Acute Lymphoblastic Leukemia Blood. 120: 289-289. DOI: 10.1182/Blood.V120.21.289.289 |
0.388 |
|
| 2012 |
Gore L, Macy ME, Mechinaud F, Narendran A, Alvaro F, Arndt CA, Barnette P, Boklan J, Cooper T, Martin L, Tcheng W, Tarassoff P, Jones MM, Meshinchi S, Arceci RJ. Interim Report of a Randomized, Open-Label, Multicenter Study to Evaluate the Safety and Efficacy of Decitabine As an Epigenetic Priming Agent When Combined with Induction Chemotherapy in Pediatric Patients (pts) with Newly Diagnosed Acute Myelogenous Leukemia (AML) Blood. 120: 1517-1517. DOI: 10.1182/Blood.V120.21.1517.1517 |
0.423 |
|
| 2011 |
Schiffman JD, Lorimer PD, Rodic V, Jahromi MS, Downie JM, Bayerl MG, Sanmann JN, Althof PA, Sanger WG, Barnette P, Perkins SL, Miles RR. Genome wide copy number analysis of paediatric Burkitt lymphoma using formalin-fixed tissues reveals a subset with gain of chromosome 13q and corresponding miRNA over expression. British Journal of Haematology. 155: 477-86. PMID 21981616 DOI: 10.1111/J.1365-2141.2011.08883.X |
0.372 |
|
| 2011 |
Mangum DS, Shams S, Downie JM, von Schwedler U, Rodic V, Engel M, Barnette P, Frazer JK, Trede N, Pei D, Cheng C, Pui C, Hunger SP, Yang JJ, Miles RR, et al. Focal 22q11.22 Loss Combined with IKZF1 Alterations Predict Very Poor Outcome in Childhood Acute Lymphoblastic Leukemia Blood. 118: 741-741. DOI: 10.1182/Blood.V118.21.741.741 |
0.392 |
|
| 2010 |
Gorman MF, Ji L, Ko RH, Barnette P, Bostrom B, Hutchinson R, Raetz E, Seibel NL, Twist CJ, Eckroth E, Sposto R, Gaynon PS, Loh ML. Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): a Therapeutic Advances in Childhood Leukemia (TACL) Consortium study. Pediatric Blood & Cancer. 55: 421-9. PMID 20658611 DOI: 10.1002/Pbc.22612 |
0.411 |
|
| 2010 |
Ko RH, Ji L, Barnette P, Bostrom B, Hutchinson R, Raetz E, Seibel NL, Twist CJ, Eckroth E, Sposto R, Gaynon PS, Loh ML. Outcome of patients treated for relapsed or refractory acute lymphoblastic leukemia: a Therapeutic Advances in Childhood Leukemia Consortium study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 648-54. PMID 19841326 DOI: 10.1200/Jco.2009.22.2950 |
0.428 |
|
| 2010 |
Tap WD, Demetri GD, Barnette P, Desai J, Kavan P, Tozer R, Friberg GR, Deng H, McCaffery I, Tolcher AW. AMG 479 in relapsed or refractory Ewing's family tumors (EFT) or desmoplastic small round cell tumors (DSRCT): Phase II results. Journal of Clinical Oncology. 28: 10001-10001. DOI: 10.1200/Jco.2010.28.15_Suppl.10001 |
0.354 |
|
| 2010 |
Schiffman JD, Lorimer PD, Rodic V, Jahromi MS, Downie JM, Bayerl MG, Perkins SL, Barnette P, Miles RR. High Resolution Genome-Wide Copy Number Analysis of Pediatric Burkitt Lymphoma Identifies Copy Number Alterations In the Majority of Patients Blood. 116: 3123-3123. DOI: 10.1182/Blood.V116.21.3123.3123 |
0.438 |
|
| 2010 |
Downie J, Barnette P, Rodic V, Frazer JK, Trede N, Devidas M, Mullighan C, Hunger S, Miles RR, Schiffman JD. T-Cell Receptor Gene Deletions Are Associated with High Risk Features and Worse Outcome In Childhood Precursor B-Cell Acute Lymphoblastic Leukemia (ALL) Blood. 116: 275-275. DOI: 10.1182/Blood.V116.21.275.275 |
0.408 |
|
| 2010 |
Miles RR, Downie J, Jahromi MS, Joshi D, Rodic V, Muschen M, Yang JJ, Evans WE, Meeker N, Trede N, Frazer JK, Barnette P, Schiffman JD. VPREB1 Deletions Occur Independent of Lambda-Light Chain Rearrangement and Predict Worse Outcome In Pediatric Acute Lymphoblastic Leukemia (ALL) Blood. 116: 273-273. DOI: 10.1182/Blood.V116.21.273.273 |
0.391 |
|
| 2009 |
Montenegro R, Vu N, Jahromi M, Boucher K, Miles RR, Barnette P, Schiffman JD. Pilot Study of Ethnic Variation in Biological Features of Childhood Acute Lymphoblastic Leukemia (ALL) in Utah. Blood. 114: 4117-4117. DOI: 10.1182/Blood.V114.22.4117.4117 |
0.366 |
|
| 2009 |
Schiffman SD, Downie J, Demarest B, Montenegro R, Rodic V, Barnette P, Miles RR. Novel Use of Molecular Inversion Probes to Interrogate Formalin-Fixed Paraffin-Embedded (FFPE) Samples of Childhood Leukemia. Blood. 114: 1589-1589. DOI: 10.1182/Blood.V114.22.1589.1589 |
0.42 |
|
| 2007 |
Tward J, Glenn M, Pulsipher M, Barnette P, Gaffney D. Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma. Leukemia & Lymphoma. 48: 1482-95. PMID 17701578 DOI: 10.1080/10428190701447346 |
0.361 |
|
| 2006 |
Wagner LM, Burger RA, Guichard SM, Raimondi SC, Santana VM, Furman WL, Barnette P, Danks MK. Pilot study to evaluate MYCN expression as a neuroblastoma cell marker to detect minimal residual disease by RT-PCR. Journal of Pediatric Hematology/Oncology. 28: 635-41. PMID 17023822 DOI: 10.1097/01.Mph.0000212976.13749.8A |
0.342 |
|
| Show low-probability matches. |